Proactive Investors - Run By Investors For Investors

Benitec Biopharma signs manufacturing deal for hepatitis C treatment

Benitec Biopharma signs manufacturing deal for hepatitis C treatment

Benitec Biopharma (ASX:BLT) has entered into an agreement with Maryland-based Omnia Biologics to manufacture material for its current first-in-man clinical trial for its TT-034 hepatitis C treatment.

This ensures the company has enough clinical material to complete the current trial.

The company is also moving to establish its own scalable manufacturing process in collaboration with third parties to supply large markets it is targeting.


Hepatitis C Treatment


TT-034 is a ddRNAi-based therapeutic that is designed to treat and potentially cure hepatitis C with a single administration.

It targets the hepatitis C viral RNA at three separate, highly conserved sites, which minimises the ability of the virus to mutate and escape the therapy.

Once it reaches the liver cells, it enters the nucleus and produces three separate short hairpin RNAs continuously for the live of the cell.

This has the potential to guard against reinfection for months to years without the need to re-treat.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full BLT profile View Profile

Benitec Biopharma Timeline

Newswire
August 18 2015

Related Articles

Cameron Durrant
March 05 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
researcher at microscope
Sat
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use